ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has received an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $6.30.

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.50 price objective (down previously from $6.50) on shares of ZIOPHARM Oncology in a research report on Monday, May 11th. Cantor Fitzgerald reaffirmed a “market perform” rating and set a $6.00 price objective on shares of ZIOPHARM Oncology in a research report on Sunday, June 21st. Jefferies Financial Group started coverage on shares of ZIOPHARM Oncology in a research report on Friday, June 19th. They set a “buy” rating and a $7.00 price objective for the company. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, May 12th. Finally, ValuEngine raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Friday, May 1st.

Large investors have recently modified their holdings of the company. Man Group plc acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $119,000. BNP Paribas Arbitrage SA lifted its stake in ZIOPHARM Oncology by 301.9% during the first quarter. BNP Paribas Arbitrage SA now owns 82,423 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 61,915 shares during the last quarter. Jefferies Group LLC acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $92,000. Principal Financial Group Inc. lifted its stake in ZIOPHARM Oncology by 7.3% during the first quarter. Principal Financial Group Inc. now owns 50,260 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 3,416 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in ZIOPHARM Oncology by 11.6% during the first quarter. BlackRock Inc. now owns 13,945,014 shares of the biotechnology company’s stock valued at $34,165,000 after purchasing an additional 1,453,295 shares during the last quarter. 46.20% of the stock is owned by institutional investors.

ZIOP stock traded up $0.07 during trading on Thursday, reaching $3.28. The stock had a trading volume of 1,470,731 shares, compared to its average volume of 2,174,149. ZIOPHARM Oncology has a 1-year low of $1.79 and a 1-year high of $7.25. The company has a current ratio of 11.56, a quick ratio of 11.56 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $687.87 million, a P/E ratio of -4.69 and a beta of 2.49. The firm has a fifty day moving average price of $3.13 and a 200 day moving average price of $3.40.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). During the same quarter in the prior year, the company posted ($0.08) earnings per share. Sell-side analysts predict that ZIOPHARM Oncology will post -0.35 EPS for the current year.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: What’s a Black Swan?

Analyst Recommendations for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.